MX2019006220A - Ligandos opioides kappa de heteroaril fenoxi benzamida. - Google Patents
Ligandos opioides kappa de heteroaril fenoxi benzamida.Info
- Publication number
- MX2019006220A MX2019006220A MX2019006220A MX2019006220A MX2019006220A MX 2019006220 A MX2019006220 A MX 2019006220A MX 2019006220 A MX2019006220 A MX 2019006220A MX 2019006220 A MX2019006220 A MX 2019006220A MX 2019006220 A MX2019006220 A MX 2019006220A
- Authority
- MX
- Mexico
- Prior art keywords
- disorder
- kappa opioid
- heteroarylphenoxy
- benzamide
- preparation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
- C07D231/20—One oxygen atom attached in position 3 or 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invención proporciona compuestos de la Formula I: (ver fórmula) y sales farmaceuticamente aceptables de los mismos, en donde las variables R1, R2, R3, R4, R9, X, m y n son como se definen en la presente; procesos para la preparacion de; intermediarios utilizados en la preparacion de; y composiciones que contienen tales compuestos o sales; y sus usos para tratar trastornos asociados con opioides kappa (?-opioide) incluyendo, por ejemplo, un trastorno neurologico, o trastorno psiquiatrico tal como un trastorno neurocognitico, trastorno de abuso de sustancias, trastorno depresivo, trastorno de ansiedad, trastorno relacionado con trauma o estres y trastorno alimenticio.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662426980P | 2016-11-28 | 2016-11-28 | |
US201762576435P | 2017-10-24 | 2017-10-24 | |
US201762585016P | 2017-11-13 | 2017-11-13 | |
PCT/IB2017/057418 WO2018096510A1 (en) | 2016-11-28 | 2017-11-27 | Heteroarylphenoxy benzamide kappa opioid ligands |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2019006220A true MX2019006220A (es) | 2019-10-07 |
Family
ID=60782279
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019006220A MX2019006220A (es) | 2016-11-28 | 2017-11-27 | Ligandos opioides kappa de heteroaril fenoxi benzamida. |
Country Status (19)
Country | Link |
---|---|
US (1) | US10316021B2 (es) |
EP (1) | EP3544972B8 (es) |
JP (1) | JP7051853B2 (es) |
CN (1) | CN110234638B (es) |
AU (1) | AU2017365123B2 (es) |
CA (1) | CA3045242A1 (es) |
DK (1) | DK3544972T3 (es) |
ES (1) | ES2947293T3 (es) |
FI (1) | FI3544972T3 (es) |
HR (1) | HRP20230518T1 (es) |
HU (1) | HUE061945T2 (es) |
IL (1) | IL266962B (es) |
MX (1) | MX2019006220A (es) |
PH (1) | PH12019501172A1 (es) |
PL (1) | PL3544972T3 (es) |
PT (1) | PT3544972T (es) |
RS (1) | RS64258B1 (es) |
TW (1) | TWI720272B (es) |
WO (1) | WO2018096510A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018154118A2 (en) * | 2017-02-24 | 2018-08-30 | Reinmueller Viktoria | Novel aromatic compounds |
US11591289B2 (en) | 2017-02-24 | 2023-02-28 | Xeniopro GmbH | Aromatic compounds |
US11266627B1 (en) | 2021-05-04 | 2022-03-08 | Janssen Pharmaceuticals, Inc. | Compositions and methods for the treatment of depression |
CN111233768B (zh) * | 2020-03-18 | 2021-08-03 | 徐州圣元化工有限公司 | 一种3-(二氟甲基)-1-甲基-1h-吡唑-4-羧酸乙酯的制备方法 |
AU2021253796B2 (en) * | 2020-04-05 | 2023-06-01 | Pfizer Inc. | Compounds and methods for the treatment of COVID-19 |
WO2023170547A1 (en) * | 2022-03-07 | 2023-09-14 | Janssen Pharmaceuticals, Inc. | Pure forms of crystalline aticaprant |
WO2023170550A1 (en) * | 2022-03-07 | 2023-09-14 | Janssen Pharmaceuticals, Inc. | Polymorph forms of aticaprant for use in treating major depressive disorder |
WO2024079733A1 (en) * | 2022-10-12 | 2024-04-18 | Adama Makhteshim Ltd. | Process for the preparation of aminopyridazine derivatives |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
WO2000035298A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Chewing gum containing medicament active agents |
GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
WO2000017162A1 (fr) * | 1998-09-21 | 2000-03-30 | Takeda Chemical Industries, Ltd. | Nouveaux derives de thiol, leur procede de production et leur utilisation |
JP2000159747A (ja) | 1998-09-21 | 2000-06-13 | Takeda Chem Ind Ltd | 新規チオ―ル誘導体、その製造法および用途 |
IT1303737B1 (it) | 1998-11-11 | 2001-02-23 | Smithkline Beecham Spa | Derivati fenilpiperidinici procedimento per la loro preparazione eloro uso come ligandi del recettore orl-1. |
DE60321207D1 (en) | 2002-09-19 | 2008-07-03 | Lilly Co Eli | Diaryläther als opioid-rezeptor antagonisten |
US7365209B2 (en) | 2003-02-11 | 2008-04-29 | Pharmacopeia, Inc. | Nitrogen heterocycle biaryls for osteoporosis and other diseases |
EP1606275B1 (en) | 2003-03-07 | 2008-08-27 | Eli Lilly And Company | Opioid receptor antagonists |
CA2517888C (en) | 2003-03-14 | 2012-05-01 | Ono Pharmaceutical Co., Ltd. | Nitrogen-containing heterocyclic derivatives and drugs containing the same as the active ingredient |
US8188277B2 (en) | 2004-08-06 | 2012-05-29 | Otsuka Pharmaceutical Co., Ltd. | Aromatic compounds for suppressing the generation of collagen |
JPWO2006088079A1 (ja) | 2005-02-18 | 2008-07-03 | 日本曹達株式会社 | 有機無機複合体 |
CA2644368A1 (en) | 2006-03-10 | 2007-09-20 | Ono Pharmaceutical Co., Ltd. | Nitrogenated heterocyclic derivative, and pharmaceutical agent comprising the derivative as active ingredient |
JP5128578B2 (ja) | 2006-04-04 | 2013-01-23 | エモディス ゲーエムベーハー | 解離性障害の治療のためのκ−オピオイド受容体アンタゴニスト含有組成物の利用 |
EP2252581B1 (en) | 2008-01-22 | 2012-06-20 | Eli Lilly And Company | Kappa selective opioid receptor antagonist |
WO2009102893A2 (en) | 2008-02-14 | 2009-08-20 | Amira Pharmaceuticals, Inc. | CYCLIC DIARYL ETHER COMPOUNDS AS ANTAGONISTS OF PROSTAGLANDIN D2 receptors |
CR11559A (es) | 2008-03-25 | 2010-10-20 | Lilly Co Eli | Antagonista del receptor opioide selectivo kappa |
US8048895B2 (en) | 2008-04-18 | 2011-11-01 | Research Triangle Institute | Kappa opioid receptor ligands |
EP3549934A1 (en) | 2008-06-27 | 2019-10-09 | Celgene CAR LLC | Heteroaryl compounds and uses thereof |
EP2379524A1 (en) | 2008-12-18 | 2011-10-26 | Boehringer Ingelheim International GmbH | Serotonin 5-ht2b receptor inhibitors |
HN2010001319A (es) | 2009-01-26 | 2013-01-15 | Lilly Co Eli | Antagonista del receptor opioide selectivo kappa |
WO2013059648A1 (en) | 2011-10-21 | 2013-04-25 | Neurotherapeutics Pharma, Inc. | 2,3,5 trisubstituted aryl and heteroaryl amino derivatives, compositions, and methods of use |
CN104684894A (zh) | 2012-10-02 | 2015-06-03 | 默克专利股份有限公司 | 吡咯烷类 |
WO2015109080A1 (en) | 2014-01-15 | 2015-07-23 | Research Triangle Institute | Kappa-opioid receptor selective opioid receptor antagonists |
US10118896B2 (en) | 2014-11-26 | 2018-11-06 | University Of Kansas | Antagonists of the kappa opioid receptor |
-
2017
- 2017-11-22 US US15/820,679 patent/US10316021B2/en active Active
- 2017-11-27 FI FIEP17818281.2T patent/FI3544972T3/fi active
- 2017-11-27 PT PT178182812T patent/PT3544972T/pt unknown
- 2017-11-27 JP JP2019528746A patent/JP7051853B2/ja active Active
- 2017-11-27 ES ES17818281T patent/ES2947293T3/es active Active
- 2017-11-27 EP EP17818281.2A patent/EP3544972B8/en active Active
- 2017-11-27 TW TW106141134A patent/TWI720272B/zh active
- 2017-11-27 HR HRP20230518TT patent/HRP20230518T1/hr unknown
- 2017-11-27 MX MX2019006220A patent/MX2019006220A/es unknown
- 2017-11-27 HU HUE17818281A patent/HUE061945T2/hu unknown
- 2017-11-27 CA CA3045242A patent/CA3045242A1/en active Pending
- 2017-11-27 DK DK17818281.2T patent/DK3544972T3/da active
- 2017-11-27 RS RS20230453A patent/RS64258B1/sr unknown
- 2017-11-27 CN CN201780084763.0A patent/CN110234638B/zh active Active
- 2017-11-27 AU AU2017365123A patent/AU2017365123B2/en active Active
- 2017-11-27 PL PL17818281.2T patent/PL3544972T3/pl unknown
- 2017-11-27 WO PCT/IB2017/057418 patent/WO2018096510A1/en active Application Filing
-
2019
- 2019-05-28 IL IL266962A patent/IL266962B/en unknown
- 2019-05-28 PH PH12019501172A patent/PH12019501172A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU2017365123B2 (en) | 2022-02-17 |
CA3045242A1 (en) | 2018-05-31 |
CN110234638B (zh) | 2022-10-21 |
US10316021B2 (en) | 2019-06-11 |
PL3544972T3 (pl) | 2023-07-24 |
JP2019535799A (ja) | 2019-12-12 |
EP3544972A1 (en) | 2019-10-02 |
AU2017365123A1 (en) | 2019-07-11 |
RS64258B1 (sr) | 2023-07-31 |
HUE061945T2 (hu) | 2023-09-28 |
CN110234638A (zh) | 2019-09-13 |
WO2018096510A1 (en) | 2018-05-31 |
US20180148432A1 (en) | 2018-05-31 |
IL266962A (en) | 2019-07-31 |
JP7051853B2 (ja) | 2022-04-11 |
EP3544972B8 (en) | 2023-06-07 |
EP3544972B1 (en) | 2023-04-26 |
TW201831460A (zh) | 2018-09-01 |
ES2947293T3 (es) | 2023-08-04 |
HRP20230518T1 (hr) | 2023-08-04 |
FI3544972T3 (fi) | 2023-06-02 |
PT3544972T (pt) | 2023-06-20 |
DK3544972T3 (da) | 2023-05-30 |
PH12019501172A1 (en) | 2019-12-11 |
TWI720272B (zh) | 2021-03-01 |
IL266962B (en) | 2022-02-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12019501172A1 (en) | Heteroarylphenoxy benzamide kappa opioid ligands | |
PH12019501941A1 (en) | Jak inhibitors containing a 4-membered heterocyclic amide | |
CL2014003181A1 (es) | Compuestos derivados de benzamidas n- sustituidas o piridinamidas n-sustituidas; composicion farmaceutica que los comprende; metodo de tratamiento; y su uso para el tratamiento de enfermedades o trastornos seleccionados de dolor, depresion y enfermedades cardiovasculares, respiratorias o psiquiatricas o combinaciones de estas. | |
MX2022001343A (es) | Compuestos y composiciones para tratar trastornos hematologicos. | |
TN2017000075A1 (en) | Compounds and compositions as raf kinase inhibitors | |
MX2022014864A (es) | Compuestos de bisamida que activan el sarcomero y sus usos. | |
MY196809A (en) | (),()-unsaturated amide compound | |
MX2019012945A (es) | Formas cristalinas de un compuesto inhibidor de jak. | |
MX2016008910A (es) | Compuestos de fenil-triazolo-piridina. | |
JO2741B1 (en) | Spiro-cyclic nitroblast as protease inhibitors | |
MX2018009659A (es) | Proceso para preparar etilenaminas superiores y derivados de etilenaminas. | |
BR112016011016A8 (pt) | derivados de fenoxietila de amina cíclica, seus usos, e composição farmacêutica. | |
SA519401322B1 (ar) | مركبات أريل كربوكساميد غير متجانسة كمثطبات لكيناز بروتين سيرين/ ثريونين متداخل مع المستقبل 2 | |
PH12017501422A1 (en) | 1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders | |
MX2018005133A (es) | Intermediarios para preparar herbicidas de piridazinona y proceso para prepararlos. | |
MX2016008909A (es) | Compuestos de isopropil triazolo piridina. | |
PH12019500822A1 (en) | Crystalline forms of eravacycline | |
PH12017501876A1 (en) | Pyridopyrimidones and their use as nmda receptor modulators | |
MX2018016339A (es) | Compuestos heterociclicos antiinfecciosos y sus usos. | |
MX2018014081A (es) | Uso de compuesto de carbamato para prevenir o tratar neuralgia trigeminal. | |
MX2021007511A (es) | Procedimiento para la preparacion de anilinas sustituidas. | |
MX2019015371A (es) | Derivados de dihidro-pirrolo-piridina. | |
MX2020008465A (es) | Clorhidrato de derivado de benzodiazepina y forma cristalina, método de preparación y aplicación del mismo. | |
PH12015502060A1 (en) | Hydrochloride salts of an antibiotic compound | |
MX2021000226A (es) | Nuevo proceso para la preparacion de diamidas antranilicas. |